A series of algorithms developed to highlight characteristics, epidemiology, and health care information related to progressive fibrosing interstitial lung disease suggests a high burden on patients and health care services.
An increased concentration of MUC5AC in the airways of lungs may play an important pathobiological role in the initiation and progression of COPD.
Using clinically important deterioration as a composite endpoint for disease progression may be beneficial in predicting long-term clinical outcomes in Japanese patients with COPD.
In patients with severe COVID-19 supported with venovenous ECMO, the early initiation of cytokine adsorption does not reduce serum IL-6 vs no initiation, and may negatively affect survival.
While a subset of people with cystic fibrosis may experience a more severe clinical course of COVID-19, they are not at an increased risk of contracting SARS-CoV-2 compared with the general population.
When administered in early COVID-19, the inhaled glucocorticoid budesonide may reduce the necessity for urgent medical care and may reduce the time to recovery.
To better understand the development of a rare clotting, investigators conducted a PF4-heparin ELISA and a PF4 ELISA to identify platelet-activating antibodies.
In patients with respiratory P aeruginosa infection, an increase in the bacterial production of elastase may increase lung tissue inflammation.
Investigators collected serum samples for anti-SARS-CoV-2 antibody testing and questionnaires to assess the longevity of antibody response to infection.
People using electronic nicotine delivery systems with cigarette-like nicotine delivery may reduce their exposure to a tobacco-specific carcinogen metabolite, even with concurrent smoking.
